Taken together, these results indicate serum UA to be a good parameter for predicting the development of NAFLD/NASH, and that XO inhibitors or uricosuric agents might have potential as treatments for ameliorating the features of NAFLD. The gene discussed is XDH; the disease is metabolic dysfunction-associated steatotic liver disease.